Disease or Syndrome
Crinetics’ Paltusotine Demonstrates Success in Second Phase III Trial for Oral Acromegaly Treatment, Prepares for FDA Filing
Crinetics Pharmaceuticals, Paltusotine, Acromegaly, Phase III trials, FDA submission, Oral treatment, Symptom reduction
FDA Grants First Approval for Orchard Therapeutics’ Gene Therapy Lenmeldy in Treating Rare Pediatric Neuron Disease
Orchard Therapeutics, Lenmeldy, FDA Approval, Metachromatic Leukodystrophy (MLD), Rare Pediatric Disease, Autologous Gene Therapy, Pre-Symptomatic Late Infantile/ Early Juvenile Patients
“Continuum Biologics’ PIPE-791 Advances with Johnson & Johnson Partnership in Initial Public Offering (IPO)”
Continuum Biologics, PIPE-791, Johnson & Johnson partnership, Initial Public Offering (IPO), Multiple sclerosis, Demyelinating diseases, Neuroinflammation, LPAR1 antagonist, Lysophosphatidic acid receptor Edg-2 antagonist
AstraZeneca Joins Price Cap Movement for Inhalers Following Boehringer Investigation
Evaluation, Inhaler, AstraZeneca, SmithKline Beecham, Prices
Contineum Launches IPO Campaign to Accelerate Multiple Sclerosis Pipeline
Contineum Therapeutics, Initial Public Offering (IPO), Johnson & Johnson (J&J) Backed, Multiple Sclerosis (MS) Pipeline, Phase II Trial, PIPE-307
Amylyx’s ALS Treatment Relyvrio Disappoints in Phase III PHOENIX Study, Company Considering Market Withdrawal
Amylyx, Relyvrio, ALS, Failure, Phase III PHOENIX Study, Market Withdrawal, Clinical Trial, Placebo, No Statistical Significance
FDA Greenlights Opdivo Combination Therapy for First-Line Bladder Cancer Treatment
Overall Survival, Combined, cisplatin, Opdivo
Boehringer Ingelheim Caps Out-of-Pocket Costs for Asthma and COPD Inhalers in the U.S.
Boehringer Ingelheim, Out-of-pocket costs, Asthma, COPD, Inhalers, $35 cap, June 1/ 2024, Uninsured and under-insured patients, List price reduction
Merck KGaA Abandons Evobrutinib Development, Emphasizes Deal-Focused Pipeline Strategy
Merck KGaA, Evobrutinib, BTK Inhibitor, Deal-driven Pipeline Strategy, Discontinuation of Development, Failed Phase 3 Trials, Multiple Sclerosis (MS) Treatment
Sionna Secures $182M Series C Funding to Advance Novel Cystic Fibrosis Treatment Pipeline
NBD1 stabilizers, ICL4 inhibitor, Cystic fibrosis, CFTR, NBD1, Cystic fibrosis, Cystic fibrosis, Sionna, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic Cystic, Cystic Cystic Cystic:, Search for the citation: